Current Report Filing (8-k)
January 09 2017 - 09:03AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): January 9, 2017
CIDARA THERAPEUTICS, INC.
(Exact Name of Registrant as Specified in its Charter)
|
|
|
|
|
Delaware
|
|
001-36912
|
|
46-1537286
|
(State of Incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
6310 Nancy Ridge Drive, Suite 101
San Diego, California 92121
(Address of principal executive offices, including zip code)
Registrants telephone number, including area code: (858)
752-6170
Check the appropriate box below if the Form
8-K
filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions:
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule
14a-12
under the Exchange Act (17 CFR
240.14a-12)
|
☐
|
Pre-commencement
communications pursuant to Rule
14d-2(b)
under the Exchange Act (17 CFR
240.14d-2(b))
|
☐
|
Pre-commencement
communications pursuant to Rule
13e-4(c)
under the Exchange Act (17 CFR
240.13e-4(c))
|
Item 7.01
|
Regulation FD Disclosure
|
On January 9, 2017, the slide presentation attached as Exhibit 99.1 will
be presented in various investor meetings by the management of Cidara Therapeutics, Inc. (the Company). Information from this slide presentation may also be used by the management of the Company in future meetings regarding the Company.
The information contained in this Item 7.01 and in Exhibit 99.1 of this Current Report on Form
8-K
shall not be
deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act,
except as expressly set forth by specific reference in such a filing.
Item 9.01.
|
Financial Statements and Exhibits
|
(d)
Exhibits
.
|
|
|
Exhibit
No.
|
|
Description
|
|
|
99.1
|
|
Slide Presentation, dated January 9, 2017.
|
1
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
|
|
|
|
|
|
Dated: January 9, 2017
|
|
|
|
IGNYTA, INC.
|
|
|
|
|
|
|
|
|
By:
|
|
/s/ Jeffrey Stein, Ph.D.
|
|
|
|
|
Name:
|
|
Jeffrey Stein, Ph.D.
|
|
|
|
|
Title:
|
|
President and Chief Executive Officer
|
2
EXHIBIT INDEX
|
|
|
Exhibit
No.
|
|
Description
|
|
|
99.1
|
|
Slide Presentation, dated January 9, 2017.
|
3
Cidara Therapeutics (NASDAQ:CDTX)
Historical Stock Chart
From Feb 2024 to Mar 2024
Cidara Therapeutics (NASDAQ:CDTX)
Historical Stock Chart
From Mar 2023 to Mar 2024